What should be the primary target of "treat to target" in psoriatic arthritis?
<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...
Main Authors: | Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Journal of Rheumatology
2018
|
פריטים דומים
-
What should be the primary target of ‘treat to target’ in PsA?
מאת: Coates, L, et al.
יצא לאור: (2018) -
Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
מאת: Coates, L, et al.
יצא לאור: (2022) -
Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
מאת: Coates, L, et al.
יצא לאור: (2019) -
Sustained very low disease activity and remission in psoriatic arthritis patients
מאת: Lubrano, E, et al.
יצא לאור: (2019) -
New approved drugs for psoriatic arthritis
מאת: F.M. Perrotta, et al.
יצא לאור: (2016-09-01)